Eutilex.Co.,Ltd (KOSDAQ:263050)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,937.00
+77.00 (4.14%)
Last updated: Jul 16, 2025
-2.22%
Market Cap68.87B
Revenue (ttm)11.25B
Net Income (ttm)-27.74B
Shares Out36.83M
EPS (ttm)-753.49
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume275,689
Average Volume1,554,438
Open1,878.00
Previous Close1,860.00
Day's Range1,809.00 - 1,976.00
52-Week Range1,163.00 - 3,700.00
Beta1.41
RSI45.25
Earnings DateAug 14, 2025

About Eutilex.Co.,Ltd

Eutilex.Co.,Ltd. engages in the discovery and development of immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases. It develops EU101, a fully humanized anti-human 4-1BB monoclonal antibody; EU103, a fully humanized therapeutic monoclonal antibody; and EU501, an 4-1BB mAb-based, tumor antigen targeting bispecific antibodies. The company was founded in 2008 and is headquartered in Seoul, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2008
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 263050
Full Company Profile

Financial Performance

In 2024, Eutilex.Co.,Ltd's revenue was 9.53 billion, an increase of 7136.10% compared to the previous year's 131.65 million. Losses were -29.17 billion, 5.22% more than in 2023.

Financial Statements

News

There is no news available yet.